ACC	acetyl-CoA carboxylase
AER	adverse event report
AEs	adverse events
ALT	alanine transaminase
AST	aspartate transaminase
APRI	aspartate aminotransferase to platelet ratio index
AUDIT-C	alcohol use disorders-concise score
BMI	body mass index
CKD	chronic kidney disease
CRP	c-reactive protein
CT	computed tomography
CV	cardiovascular
DPP-4	dipeptidyl-peptidase-4
EMA	European Medical Agency
FAERS	FDA Adverse Events Reporting System
FDA	Food and drug administration
FXR	farnesoid X receptor
GLP-1 RA	glucagon-like peptide 1 receptor agonist
GI	gastrointestinal
GIP	gastrointestinal peptide
HbA1c	glycated hemoglobin
HU	hounsfield unit
kPa	kilopascal
LFC	liver fat content
LSM	liver stiffness measurement
MALO	major adverse liver outcome
MASH	metabolic dysfunction-associated steatohepatitis
ML	machine learning
MRE	magnetic resonance elastography
MRI-PDFF	magnetic resonance imaging-proton density fat fraction
NAFLD	nonalcoholic fatty liver disease
NAION	non-arteritic anterior ischemic optic neuropathy
NASH	nonalcoholic steatohepatitis
NITs	Non-invasive tests
OTTES	observational target trial emulation study
OD	once daily
OW	once weekly
PRAC	Pharmacovigilance Risk Assessment Committee
RCT	randomized controlled trial
sc	subcutaneous
SELECT	semaglutide effects on cardiovascular outcomes in people with overweight or obesity
SH	steatohepatitis
SLD	steatotic liver disease
STOP	semaglutide treatment effect on coronary atherosclerosis progression
SUSTAIN	semaglutide unabated sustainability in treatment of type 2 diabetes
T2D	type 2 diabetes